TITLE

Trials Planned to Confirm Efficacy of Tenofovir Microbicide Gel

AUTHOR(S)
McEnery, Regina
PUB. DATE
November 2010
SOURCE
VAX;Nov2010, Vol. 8 Issue 6, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the plan to conduct two confirmatory trials on the efficacy of Tenofovir Microbicide Gel in preventing HIV infections, which will involve 3,000 women in South Africa.
ACCESSION #
56437495

 

Related Articles

  • Antiretroviral Medication and HIV Prevention: New Steps Forward and New Questions. Mayer, Kenneth H.; Krakower, Douglas // Annals of Internal Medicine;2/21/2012, Vol. 156 Issue 4, p312 

    During the past 2 years, several pivotal clinical trials have proven that the use of antiretrovirals by HIV-infected and at-risk uninfected persons can decrease the probability of HIV being transmitted sexually. The initial chemoprophylaxis studies evaluated tenofovir administered topically or...

  • Widespread tenofovir gel use has substantial impact in South Africa.  // PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p1 

    The article discusses research analysis in 2011 that claims widespread use of tenofovir gel in South Africa could prevent more than two million new HIV infections and save one million lives over 20 years. The research was conducted by the World Health Organization (WHO), the Centre for the AIDS...

  • Letter from the Executive Director. Caldwell, Katy // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p3 

    An introduction is presented in which the author discusses various reports within the issue including one about adherence to Truvada as pre-exposure prophylaxis (PrEP), another one about a PrEP trial in gay and bisexual men and transgender women, and one about integrating PrEP into practice.

  • HIV gel failure.  // New Scientist;12/3/2011, Vol. 212 Issue 2841, p4 

    The article focuses on the discontinuation of a U.S. National Institutes of Health (NIH) clinical trial of an HIV prevention therapy that used a vaginal gel formulation of the drug tenofovir after the study did not produce any improvement in infection rates.

  • Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection. Lyseng-Williamson, Katherine A.; Scott, Lesley J. // Clinical Drug Investigation;2012, Vol. 32 Issue 10, p715 

    The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Evipleraâ„¢ [EU]; Compleraâ„¢ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient...

  • NY leads search for AIDS vaccine. Scott, Gale // Crain's New York Business;8/21/2006, Vol. 22 Issue 34, p1 

    This article reports that clinical trials of several AIDS vaccines, including Merck & Co. Inc.'s AD-5 vaccine, are continuing at many major medical institutions in Manhattan, New York City. According to Beryl Koblin, head of the Laboratory of Infectious Disease Prevention for the New York Blood...

  • Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. Haberer, Jessica E.; Baeten, Jared M.; Campbell, James; Wangisi, Jonathan; Katabira, Elly; Ronald, Allan; Tumwesigye, Elioda; Psaros, Christina; Safren, Steven A.; Ware, Norma C.; Thomas, Katherine K.; Donnell, Deborah; Krows, Meighan; Kidoguchi, Lara; Celum, Connie; Bangsberg, David R. // PLoS Medicine;Sep2013, Vol. 10 Issue 9, p1 

    : Jessica Haberer and colleagues investigate the association between high adherence to antiretroviral pre-exposure prophylaxis and HIV transmission in a substudy of serodiscordant couples participating in a clinical trial. Please see later in the article for the Editors' Summary

  • Who's prepared to make PrEP work? Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p5 

    Tenofovir/emtricitabine (TDF/FTC) won FDA approval for preexposure prophylaxis (PrEP) after three placebo-controlled trials demonstrated that once-daily TDF/FTC lowers HIV acquisition risk in gay and bisexual men and heterosexual women and men. In the one trial that found no HIV protection with...

  • Quad Doesn't Disappoint: 4Q NDA Filing on Tap for Gilead. Powers, Marie // BioWorld Today;9/21/2011, Vol. 22 Issue 183, p1 

    The article reports on the second pivotal Phase III trial of the HIV Quad regimen, which includes elvitegravir, cobicistat, emtricitabin and tenofovir disoproxil fumarate, from Gilead Sciences Inc. The trial reportedly meet the expectation of Gilead Sciences and analysts by showing...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics